phosphoric acid mono-{2-[1-(2-amino-6-oxo-1,6-dihydro-purin-9-yl)-2-hydroxy-ethoxy]-3-hydroxy-propyl} ester | 52114-73-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: phosphoric acid mono-{2-[1-(2-amino-6-oxo-1,6-dihydro-purin-9-yl)-2-hydroxy-ethoxy]-3-hydroxy-propyl} ester
• 英文别名: [(2S)-2-[(1R)-1-(2-amino-6-oxo-1H-purin-9-yl)-2-hydroxyethoxy]-3-hydroxypropyl] dihydrogen phosphate
• CAS: 52114-73-5
• 化学式: C₁₀H₁₆N₅O₈P
• 分子量: 365.24
• InChiKey: GAHFZARWKCTQPJ-NTSWFWBYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.3
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  202
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• [EN] MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING<br/>[FR] ANALOGUES DE COIFFES ARNM ET PROCÉDÉS DE COIFFAGE D'ARNM
  申请人：MODERNATX INC

  公开号：WO2017066793A1

  公开（公告）日：2017-04-20

  The present disclosure relates to cap analogs of formula (I) as defined in claim 1, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

  本公开涉及公式（I）中定义的帽子类似物，其可以导致高水平的帽子效率和转录以及改善的翻译效率。本公开还涉及用于制备帽子类似物和使用包含此类类似物的mRNA物种的方法，以及包含新型帽子类似物的试剂盒。
• [EN] UNA OLIGOMERIC AGENTS FOR STIMULATING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR AND USES THEREOF<br/>[FR] AGENTS OLIGOMÈRES UNA POUR LA STIMULATION DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE IMPLIQUÉ DANS LA FIBROSE KYSTIQUE ET LEURS UTILISATIONS
  申请人：ARCTURUS THERAPEUTICS INC

  公开号：WO2017027814A1

  公开（公告）日：2017-02-16

  This invention encompasses compounds, structures, and compositions useful in methods for medical therapy, in general, for stimulating cystic fibrosis transmembrane conductance regulator (CFTR) in a subject. The compounds can comprise UNA monomers and nucleic acid monomers, and are targeted to inhibit BGAS lncRNA. The molecules of this invention can be used as active pharmaceutical ingredients in compositions for ameliorating or treating a disease associated with CFTR function, including cystic fibrosis.
• [EN] ALLELE SELECTIVE GENE EDITING AND USES THEREOF<br/>[FR] ÉDITION DE GÈNES ALLÈLE SÉLECTIVE ET UTILISATIONS ASSOCIÉES
  申请人：ARCTURUS THERAPEUTICS INC

  公开号：WO2017053431A2

  公开（公告）日：2017-03-30

  This invention encompasses compounds, structures, compositions and methods for therapeutic guide molecules that direct CRISPR gene editing. A guide molecule for directing gene editing can be allele selective, or disease allele selective, and can exhibit reduced off target activity. A guide molecule can be composed of monomers, including UNA monomers, nucleic acid monomers, and modified nucleotides, wherein the compound is targeted to a genomic DNA. The guide molecules of this invention can be used as active ingredients for editing or disrupting a gene in vitro, ex vivo, or in vivo.
• [EN] MRNA CAP ANALOGS WITH MODIFIED SUGAR<br/>[FR] ANALOGUES DE COIFFE D'ARNM AVEC SUCRE MODIFIÉ
  申请人：MODERNATX INC

  公开号：WO2017066789A1

  公开（公告）日：2017-04-20

  The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.
• [EN] TRINUCLEOTIDE MRNA CAP ANALOGS<br/>[FR] ANALOGUES DE COIFFES D'ARNM TRINUCLÉOTIDIQUES
  申请人：MODERNATX INC

  公开号：WO2017066797A1

  公开（公告）日：2017-04-20

  The present disclosure relates to cap analogs of formula (I) as defined in claim 1, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.